20/20 Biolabs, Inc. (AIDX) AI Stock Analysis

20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests designed for the early detection and prevention of cancers and chronic diseases. The company offers OneTest for Cancer, a multi-cancer early detection test, and OneTest for Longevity, which measures inflammatory biomarkers. Additionally, it operates the Clinical Lab Innovation Axcelerator (CLIAx), a CLIA laboratory catering to overseas diagnostics start-ups. Founded in 2000 and based in Gaithersburg, Maryland, the company was formerly known as 20/20 GeneSystems, Inc. before changing its name in March 2025, and currently operates with 4 employees.

20/20 Biolabs saw revenue drop from $11.1M in FY2022 to $1.4M in FY2023, representing an 87.1% decline. The business has since shown top-line recovery, posting revenue growth of 23.0% in FY2024 to $1.8M and 16.7% in FY2025 to reach $2.0M. Gross margin improved from 7.7% in FY2023 to 20.6% in FY2024 and 29.6% in FY2025. However, profitability remains deeply negative, with FY2025 operating margin at -162.9% and net income at -$3.7M. For the latest quarter ended June 30, 2026, quarterly revenue growth YoY was 36.5%, while trailing twelve-month revenue reached $2.0M with a net profit margin of -285.0%.

As of June 30, 2026, 20/20 Biolabs held $4.5M in cash and short-term investments and total debt of $572,448, resulting in net cash of $4.0M. Total assets stood at $6.1M against shareholders' equity of $3.2M. The company maintains short-term liquidity with a current ratio of 1.99 and a debt-to-equity ratio of 0.18. In FY2025, operating cash flow and free cash flow were both -$1.92B, while R&D expense totaled $592,569.

At a last close of $0.26, 20/20 Biolabs has a market capitalization of $3.3M and an enterprise value of $1.5M. The stock trades at a price-to-sales multiple of 1.6x and an EV-to-revenue multiple of 0.7x, both well below the median of its US-listed Healthcare peers, which trade at a price-to-sales multiple of 4.1x. Its price-to-book multiple is 3.4x. The shares trade at their 52-week low of $0.26, down from a 52-week high of $50.00, during a period where the S&P 500 returned 16.8% over the past year.

Wall Street coverage includes 1 analyst rating, categorized as Buy, with 0 Hold and 0 Sell recommendations. The mean price target is $5.00, which sits 1823.1% above the last close of $0.26. For the current fiscal year ending December 31, 2026, consensus estimates project revenue of $2.9M and an EPS of -$0.42. For the next fiscal year, the single analyst covering the firm anticipates revenue to expand 95.7% to $5.8M and an EPS of -$0.38. The next earnings date is November 13, 2026.

This page is an AI-written research summary of 20/20 Biolabs, Inc. (AIDX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: AIDX income statement, AIDX balance sheet, AIDX key metrics, AIDX analyst forecast, AIDX chart. See the AIDX stock overview for the latest quote and news.